Abstract
Brian B. Graham, Joan F. Hilton, Michael H. Lee, Dara Fonseca Balladares, Farbod N. Rahaghi, Raúl San José Estépar, Claudia Mickael, Rodrigo Luís Barbosa Lima, Camila M.C. Loureiro, Juliana Lucena, Rudolf K.F. Oliveira, Ricardo de Amorim Corrêa
Abstract
Rights: ALLOWED · cc-by · Source: journal-auto-sync:external:CROSSREF_ISSN
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension
10.1183/13993003.00879-2022 · 2023
Clinical characteristics and transplant-free survival across the spectrum of pulmonary vascular disease
10.1016/j.jacc.2022.05.038 · 2022
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis
10.1016/s1473-3099(22)00221-3 · 2022
Schistosomiasis pulmonary arterial hypertension
10.3389/fimmu.2020.608883 · 2020
Characteristic sonographic features of schistosomal periportal fibrosis
10.2214/ajr.143.1.69 · 1984
The causal role of IL-4 and IL-13 in schistosoma mansoni pulmonary hypertension
10.1164/rccm.201410-1820oc · 2015
Portopulmonary hypertension: results from a 10-year screening algorithm
10.1002/hep.21431 · 2006
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease
10.1164/rccm.200809-1472oc · 2009
The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis
10.1111/liv.13589 · 2018
Shear stress-exposed pulmonary artery endothelial cells fail to upregulate HSP70 in chronic thromboembolic pulmonary hypertension
10.1371/journal.pone.0242960 · 2020
Main pulmonary arterial wall shear stress correlates with invasive hemodynamics and stiffness in pulmonary hypertension
10.1086/685024 · 2016
Portopulmonary hypertension: from bench to bedside
10.3389/fmed.2020.569413 · 2020
Estrogen signaling and portopulmonary hypertension: the pulmonary vascular complications of liver disease study (PVCLD2)
10.1002/hep.31314 · 2021
Treatment of portopulmonary hypertension (PoPH): a review
10.1016/j.liver.2022.100071 · 2022
Schistosomiasis-associated pulmonary arterial hypertension: a systematic review
10.1183/16000617.0089-2019 · 2020
Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups
10.1111/j.1600-6143.2008.02384.x · 2008
Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol
10.1002/lt.21174 · 2007
Portopulmonary hypertension in the current era of pulmonary hypertension management
10.1016/j.jhep.2020.02.021 · 2020
Hemostatic dysfunction is increased in patients with hepatosplenic schistosomiasis mansoni and advanced periportal fibrosis
10.1371/journal.pntd.0002314 · 2013
Risk factors for portopulmonary hypertension in patients with cirrhosis: a prospective, multicenter study
10.1007/s12072-022-10456-y · 2023
Prevalence and associated factors of portopulmonary hypertension in patients with portal hypertension: a case-control study
10.1155/2021/5595614 · 2021
COR pulmonale due to chronic infestation with schistosoma haematobium
1964
TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension
10.1038/ncomms15494 · 2017
Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni
10.1161/circulationaha.113.003072 · 2013
Morbidity and mortality due to Schistosoma mansoni related periportal fibrosis: could early diagnosis of varices improve the outcome following available treatment modalities in sub Saharan Africa? A scoping review
10.3390/tropicalmed5010020 · 2020
Noninvasive prediction of large esophageal varices in chronic liver disease patients
10.4103/1319-3767.58767 · 2010
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis
10.1002/hep.21907 · 2007
Pulmonary arterial hypertension caused by congenital extrahepatic portocaval shunt: a case report
10.1186/s12872-019-1124-1 · 2019
Cardiopulmonary manifestations of portovenous shunts from congenital absence of the portal vein: pulmonary hypertension and pulmonary vascular dilatation
10.1111/j.1399-3046.2010.01355.x · 2011
Congenital absence of the portal vein as a rare cause of portopulmonary hypertension-a case study series
2022
Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension
10.1164/rccm.201807-1236oc · 2019
Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension
10.4103/2045-8932.110445 · 2013
Role of soluble endoglin in BMP9 signaling
10.1073/pnas.1816661116 · 2019
TGF beta and IL13 in Schistosomiasis mansoni associated pulmonary arterial hypertension; a descriptive study with comparative groups
10.1186/1471-2334-14-282 · 2014
Hypercoagulability in pulmonary hypertension
10.1016/j.ccm.2018.04.005 · 2018
Histometrical investigation of the pulmonary artery in severe hepatic disease
10.1002/path.1711430106 · 1984
Coexistent pulmonary and portal hypertension: morphologic and clinical features
10.1016/s0735-1097(87)80123-7 · 1987
Significant intrapulmonary Schistosoma egg antigens are not present in schistosomiasis-associated pulmonary hypertension
10.4103/2045-8932.93544 · 2011
Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil
2019
Cardiopulmonary manifestations of hepatosplenic schistosomiasis
10.1161/circulationaha.108.803221 · 2009
PULSAR trial investigators. Sotatercept for the treatment of pulmonary arterial hypertension
10.1056/nejmoa2024277 · doi-reference
STELLAR trial investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension
10.1056/nejmoa2213558 · doi-reference
HIV and Schistosoma co-exposure leads to exacerbated pulmonary endothelial remodeling and dysfunction associated with altered cytokine landscape
10.3390/cells11152414 · doi-reference
Persistent schistosomal pulmonary hypertension in a patient after reversion of a hepato-splenic form: presentation of a case
10.1590/s0037-86821986000300009 · doi-reference
The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension
10.1378/chest.11-0483 · doi-reference
Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies
10.1016/s0001-706x(00)00125-x · doi-reference
Effect of specific therapy on the prevention and reversal of severe forms of schistosomiasis
10.1590/s0074-02761987000800062 · doi-reference
Evidence of pulmonary vascular reverse remodeling after pulmonary artery banding performed in early infancy in patients with congenital heart defects
10.1253/circj.cj-17-0379 · doi-reference
Haemodynamic unloading reverses occlusive vascular lesions in severe pulmonary hypertension
10.1093/cvr/cvw070 · doi-reference
Does portopulmonary hypertension impede liver transplantation in cirrhotic patients? A French multicentric retrospective study
10.1097/tp.0000000000001981 · doi-reference
Long-term outcome in liver transplantation candidates with portopulmonary hypertension
10.1002/hep.28990 · doi-reference
Portopulmonary hypertension: prognosis and management in the current treatment era – results from the REHAP registry
10.1111/imj.14751 · doi-reference
Behçet’s syndrome: pulmonary vascular disease
10.1097/bor.0000000000000131 · doi-reference
Hughes-Stovin syndrome
10.1186/1750-1172-6-15 · doi-reference
Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension
10.1186/s12890-015-0115-y · doi-reference
Th2 CD4+ T cells are necessary and sufficient for schistosoma-pulmonary hypertension
10.1161/jaha.119.013111 · doi-reference
Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension
10.1016/j.jinf.2013.08.004 · doi-reference